SCHEMBL4187048

SCHEMBL4187048

CN1CC[CH][C@H]1C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347202 1.00
SCHEMBL4181741 1.00
SCHEMBL1433472 0.88 CYP3A4 (0.31)
SCHEMBL3749163 0.88 CYP3A4 (0.31)
SCHEMBL4705448 0.86 L3MBTL1 (0.31)
SCHEMBL4521568 0.79 POLB (0.32)
SCHEMBL3331945 0.77
SCHEMBL10002497 0.76 GBA1 (0.37)
SCHEMBL2686807 0.76 GBA1 (0.37)
SCHEMBL2687375 0.75 POLB (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233833-B1 NOVEL COMPOUNDS CHIESI FARM SPA (IT) 2019-02-20 EP claimed
EP-3233833-A1 NOVEL COMPOUNDS Chiesi Farmaceutici S.p.A. (IT) 2017-10-25 EP claimed
US-9409870-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-09 US claimed
WO-2016096638-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-23 WO claimed
US-20160168101-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-16 US claimed
US-20090076062-A1 Organic Compounds MAIBAUM JUERGEN KLAUS 2009-03-19 US claimed
US-20260034107-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS VTV THERAPEUTICS LLC (US) 2026-02-05 US disclosed
US-20260027090-A1 Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity VTV THERAPEUTICS LLC (US) 2026-01-29 US disclosed
US-20230312548-A1 SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF VTV THERAPEUTICS LLC 2023-10-05 US disclosed
US-11649230-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2023-05-16 US disclosed
US-20230093476-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS VTV THERAPEUTICS LLC 2023-03-23 US disclosed
US-20220169641-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof VTVX HOLDINGS II LLC 2022-06-02 US disclosed
US-20210338644-A1 Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications VTV THERAPEUTICS LLC 2021-11-04 US disclosed
US-9409870-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-09 US disclosed
WO-2016096638-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-23 WO disclosed
US-20160168101-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2016-06-16 US disclosed
WO-2016089648-A1 BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF VTV THERAPEUTICS LLC (US) 2016-06-09 WO disclosed
US-8759535-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof HIGH POINT PHARMACEUTICALS, LLC (US) 2014-06-24 US disclosed
EP-2536285-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF High Point Pharmaceuticals, LLC (US) 2012-12-26 EP disclosed
US-20090076062-A1 Organic Compounds MAIBAUM JUERGEN KLAUS 2009-03-19 US disclosed